Market revenue in 2023 | USD 391.7 million |
Market revenue in 2030 | USD 644.8 million |
Growth rate | 7.4% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Research & Manufacturing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Research & Manufacturing |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Roche Holding AG, Qiagen NV, Becton Dickinson & Co, Siemens Healthineers AG ADR, Thermo Fisher Scientific Inc, Hologic Inc, Koninklijke Philips NV, Illumina Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 65.61% in 2023. Horizon Databook has segmented the UK blood cancer diagnostics market based on hospitals, outpatient facilities, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
The market in the UK is driven by rising prevalence of cancer, including blood cancers, and supportive government initiatives for early cancer diagnosis. Cancer Research UK reports that there are around 40,000 new cases of blood cancer diagnosed annually in the UK, with leukemia accounting for 10,300 cases in the UK every year. Overall, 250,000 people in the UK are currently living with blood cancer.
In addition, ongoing government and corporate partnerships in the country drive market growth. For example, Blood Cancer UK highlighted its charity's partnerships with various corporate entities. These partnerships support the charity's life-saving work; for instance, Blood Cancer UK has raised USD 1 million through a partnership with Omaze, which would fund crucial research.
Furthermore, in April 2024, the University Hospitals of North Midlands (UHNM) launched a new charity partnership with the Blood wise charity to improve the experience of blood cancer patients. The partnership aims to provide emotional support, financial assistance, and practical help for patients undergoing treatment at UHNM.
Horizon Databook provides a detailed overview of country-level data and insights on the UK blood cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into UK blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account